PERG testing reveals subclinical optic nerve changes that may be critical for deciding when to start therapy to avoid vision loss from glaucoma progression. André Mermoud, MD, explains.
Progress on several fronts is creating optimism that retinal ganglion cell (RGC) replacement may become a reality for preserving or restoring vision in patients with glaucoma. Here’s why.
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: %%Member_Busname%% %%Member_Addr%% %%Member_City%%, %%Member_State%%, %%Member_PostalCode%%, %%Member_Country%%
